Nadia D. M.
- Country
- Italy
- Department
- Unità Radioterapia
Research Overview
Data & Insights
Has run more than one trial at 0 of 19 partner sites.
Specializations
Hematologic Malignancies
The investigator conducts studies on acute myeloid leukemia in adult patients.
Research also addresses treatment strategies for chronic lymphocytic leukemia and related disorders.
- Targeted therapies for AML in remission
- Combination regimens for CLL/SLL
- Biomarker-driven approaches in leukemic populations
- Post‑transplant outcomes in hematologic disease
Efforts aim to improve survival and quality of life for patients with blood cancers.
Solid Tumor Oncology
Clinical investigations include advanced breast cancer in elderly cohorts.
Work extends to non‑small cell lung cancer and metastatic disease settings.
Additional focus is placed on muscle‑invasive bladder cancer undergoing neoadjuvant therapy.
- Radiotherapy versus endocrine therapy in early breast cancer
- Neoadjuvant immunotherapy combinations for bladder cancer
- Precision medicine in HER2‑expressing solid tumors
- Chemotherapy optimization for pancreatic ductal adenocarcinoma
These programs support therapeutic innovation across multiple organ sites.
Sleep and Hypersomnia Disorders
The investigator evaluates novel agents for narcolepsy type 1 and related sleep conditions.
Research also encompasses treatment of idiopathic hypersomnia and excessive daytime sleepiness.
- Clinical efficacy of wake‑promoting compounds in narcolepsy
- Safety profiling of adjunctive therapy for hypersomnia
- Long‑term outcome monitoring in sleep disorder cohorts
- Patient‑reported outcomes for daytime alertness
Goals include restoring normal sleep–wake cycles and functional capacity.
Immune‑Mediated Inflammatory Diseases
Studies target biologic interventions for eosinophilic esophagitis and related conditions.
Additional work focuses on eosinophilic granulomatosis with polyangiitis management.
Investigations also address hypereosinophilic syndrome therapies.
- Anti‑IL‑5 strategies for eosinophilic gastrointestinal disease
- Monoclonal antibody trials in EGPA remission
- Safety and efficacy of novel agents in HES
- Biomarker development for eosinophil‑driven pathology
These efforts seek to modulate pathogenic immune pathways.
Cardiovascular and Metabolic Risk
Clinical programs investigate lipid‑lowering approaches for atherosclerotic cardiovascular disease.
Research includes assessment of novel agents in patients with elevated lipoprotein(a).
- Outcome studies on cardiovascular event reduction
- Long‑term safety of Lp(a)‑targeted therapies
- Risk stratification in established cardiovascular disease
- Prevention strategies for type 1 diabetes autoimmunity
The work aims to mitigate major adverse cardiac events and metabolic complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
